Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone

dc.contributor.authorSano, F.
dc.contributor.authorCortez, G. K.
dc.contributor.authorSolé, Dirceu [UNIFESP]
dc.contributor.authorNaspitz, Charles Kirov [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:31:02Z
dc.date.available2016-01-24T12:31:02Z
dc.date.issued2000-04-01
dc.description.abstractBackground: Inhaled corticosteroids are highly effective in the treatment of asthma at all ages, and their use in younger children is increasing. There are no data currently available on the treatment of infants with acute wheeze and dyspnea with nebulized budesonide.Objective: Our purpose was to assess the clinical effect of nebulized budesonide in infants with acute wheeze and dyspnea.Methods: A prospective study was performed comparing the addition of nebulized budesonide 0.25 mg every 6 hours (group A, n = 32) and nebulized ipratropium bromide 0.1 mg every 6 hours (group B, n = 39) with the normal treatment regimen with intravenous fluid, hydrocortisone, and nebulized fenoterol. A clinical score was made at admission and every 12 hours. the score included wheezing and costal retraction (0-6) and respiratory rate (counts per minute).Results: Seventy-one infants aged 3 to 24 months were studied (42 boys). A statistically significant reduction was seen in clinical score and respiratory rate in both groups 12 hours after admission. the children who received budesonide improved significantly faster than the children who received ipratropium bromide, and the hospitalization period was significantly lower in the budesonide group (66.4 hours) compared with the ipratropium bromide group (93 hours) (P <.01). Three patients from the budesonide group and 2 from the ipratropium bromide group were readmitted within the first 4 weeks.Conclusion: Treatment of infants with acute wheeze with nebulized budesonide is associated with faster clinical improvement and reduction in hospital stay period.en
dc.description.affiliationUniversidade Federal de São Paulo, Hosp Nipobrasileiro, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Pediat, Div Allergy & Clin Immunol & Rheumatol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Hosp Nipobrasileiro, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Pediat, Div Allergy & Clin Immunol & Rheumatol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent699-703
dc.identifierhttp://dx.doi.org/10.1067/mai.2000.104784
dc.identifier.citationJournal of Allergy and Clinical Immunology. St Louis: Mosby-year Book Inc, v. 105, n. 4, p. 699-703, 2000.
dc.identifier.doi10.1067/mai.2000.104784
dc.identifier.issn0091-6749
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/26276
dc.identifier.wosWOS:000086604100006
dc.language.isoeng
dc.publisherMosby-year Book Inc
dc.relation.ispartofJournal of Allergy and Clinical Immunology
dc.rightsAcesso aberto
dc.subjectasthmaen
dc.subjectbudesonideen
dc.subjectinhaled steroidsen
dc.subjectefficacyen
dc.subjectinfantsen
dc.titleInhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisoneen
dc.typeArtigo
Arquivos